The highest resolution SNV-based liquid biopsies are still unable to confidently differentiate cured cases from relapsing cases when disease burden is low. Spontaneous and benign SNVs occur frequently enough to obscure the scant presence of tumor-associated SNVs. The inherent error rate of NGS-based testing can further mask low-allelic frequency ctDNA mutations. This background noise results in missed relapses hiding in plain sight.
Single nucleotide variations are common and counting them can be inconclusive due to the inherent error rates of NGS. But multiple SNVs found on a short sequencing read (a.k.a. phased variants, or PVs) can be uniquely attributed to malignant cells. PVs commonly occur in all types of cancers, and by specifically monitoring tumor-specific PVs, we have attained unmatched MRD sensitivity.
By leveraging this untapped biology in cancers, we’re able to identify MRD at levels below the detection limit of conventional NGS-based ctDNA assays. We cut the noise that leading error suppression methods like duplex sequencing and barcoding can’t.
Our proprietary assays detect MRD across liquid and solid tumors with unprecedented sensitivity and specificity.
In lymphoma and other blood cancers, validated mutational signatures eliminate the need for customized assays, expediting MRD-guided research and treatment with personalized analysis, from off-the-shelf panels.
Unlike personalized MRD assays that require exome sequencing and patient-specific panel design, Foresight’s Lymphoma Recurrence Test is an off-the-shelf panel that can be used to measure extremely low amounts of ctDNA from plasma, giving up to 100X improved sensitivity of cancer detection that results in identifying recurrence an average of 200 days earlier* than conventional methods.
Compare germline DNA with pre-treatment plasma DNA for personalized PV genotyping via targeted sequencing.
No tumor sample needed for assay personalization.
Mid- and end-of-treatment plasma ctDNA assayed for MRD assessment.
Treatment plan is informed by ctDNA levels.
Post-treatment plasma DNA assayed for longitudinal cancer surveillance.
No tumor samples or customization needed
Assays performed at our CLIA-certified lab
Our Solid Tumor Recurrence Test is personalized based on patient-specific phased variants that are identified with whole-genome sequencing. It offers the same degree of sensitivity as our Lymphoma Recurrence Test and the ability to track oncogenic and clinically relevant SNVs in addition to other tumor-specific phased variants.More About Solid Tumor Recurrence Test